Yongin-si, South Korea

Sae Yeon Lee

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 6.2

ph-index = 1


Company Filing History:


Years Active: 2017-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Topical Treatments: The Contributions of Sae Yeon Lee

Introduction

Sae Yeon Lee, an inventive mind based in Yongin-si, South Korea, has made significant strides in the field of pharmaceutical compositions. With a total of two patents to his name, Lee focuses on developing topical treatments that effectively target skin diseases while minimizing systemic absorption and toxicity.

Latest Patents

Sae Yeon Lee's latest work involves a unique formulation of a topical anti-inflammatory pharmaceutical composition utilizing zileuton in a cream form. This innovation is designed to maintain stability at room temperature and to be applied topically, thereby maximizing medical effects and reducing unwanted absorption throughout the body. The goal of this composition is to provide suitable treatment for skin conditions caused by leukotrienes, thus offering a targeted approach to managing inflammatory responses in affected individuals.

Career Highlights

Lee is currently affiliated with Qurient Co., Ltd., where he continues to push the boundaries of pharmaceutical innovation. His experience and dedication have contributed to the advancement of topical treatments in the pharmaceutical sector, showcasing the importance of safe and effective therapies.

Collaborations

In his journey of innovation, Sae Yeon Lee has collaborated with talented individuals like Ki Yean Nam and Jeong Jun Kim. Together, they bring a wealth of knowledge and expertise to the projects they undertake, ensuring that their developments are both scientifically sound and practical for real-world applications.

Conclusion

As a dedicated inventor, Sae Yeon Lee's contributions to the realm of topical pharmaceutical compositions highlight the potential for innovative solutions in treating skin diseases. Through his work with Qurient Co., Ltd. and his collaborative efforts, he continues to pave the way for advancements in patient care and therapeutic efficacy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…